FDA Approves Botox Challenger Daxxify for Frown Lines

by Medscape • 2022/09/08 • 0 Comments

DaxibotulinumtoxinA-lanm is the first and only peptide-formulated neuromodulator to reduce frown lines, with results lasting longer than conventional neuromodulators, according to the manufacturer.
Medscape Medical News

Full Story →

← Global Retinal Imaging Devices Market Report 2022: Integrating Artificial Intelligence in Retinal Imaging Devices Key for Future Growth – ResearchAndMarkets.com

Nonmydriatic Handheld Fundus Cameras Global Market Report 2022: Steady Pace of Technological Advancements Driving Sector – ResearchAndMarkets.com →

Post navigation